GC
TBPH icon

Guggenheim Capital’s Theravance Biopharma TBPH Stock Holding History

Guggenheim Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197K Buy
+11,570
New +$192K ﹤0.01% 1651
2018
Q4 		– Sell
-7,349
Closed -$240K – 2362
2018
Q3 		$240K Buy
+7,349
New +$200K ﹤0.01% 2282
2015
Q2 		– Sell
-216,396
Closed -$3.75M – 3093
2015
Q1 		$3.75M Sell
216,396
-11,147
-5% -$204K 0.01% 1322
2014
Q4 		$3.4M Buy
227,543
+26,819
+13% +$467K 0.01% 1350
2014
Q3 		$4.63M Buy
200,724
+261
+0.1% +$7.57K 0.01% 1238
2014
Q2 		$6.39M Buy
+200,463
New +$6.03M 0.02% 1054

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Guggenheim Capital's TBPH Position: Q2 2026 in Review

Guggenheim Capital opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 11,570 shares worth $197K. The stake represents ﹤0.01% of the portfolio and ranks #1651 among its holdings. This is a return to the name: Guggenheim Capital previously reported a position in TBPH as recently as Q3 2018.

Guggenheim Capital first reported a position in TBPH in Q2 2014 and has held it in 6 quarters since. The position peaked at $6.39M in Q2 2014. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Guggenheim Capital held 11,570 shares of Theravance Biopharma worth $197K as of Q2 2026.
  • Theravance Biopharma was a new Guggenheim Capital position in Q2 2026.
  • Theravance Biopharma made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1651 holding.
  • Guggenheim Capital first reported a position in Theravance Biopharma in Q2 2014 and has held it in 6 quarters since.
  • Guggenheim Capital's Theravance Biopharma position peaked at $6.39M in Q2 2014.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.